JP2023541877A5 - - Google Patents

Info

Publication number
JP2023541877A5
JP2023541877A5 JP2023515725A JP2023515725A JP2023541877A5 JP 2023541877 A5 JP2023541877 A5 JP 2023541877A5 JP 2023515725 A JP2023515725 A JP 2023515725A JP 2023515725 A JP2023515725 A JP 2023515725A JP 2023541877 A5 JP2023541877 A5 JP 2023541877A5
Authority
JP
Japan
Prior art keywords
treatment
patient
cladribine
weeks
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541877A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/074928 external-priority patent/WO2022053608A1/en
Publication of JP2023541877A publication Critical patent/JP2023541877A/ja
Publication of JP2023541877A5 publication Critical patent/JP2023541877A5/ja
Pending legal-status Critical Current

Links

JP2023515725A 2020-09-10 2021-09-10 自己免疫障害の処置のための新規の処置レジメン Pending JP2023541877A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202062706795P 2020-09-10 2020-09-10
US62/706,795 2020-09-10
US202062706819P 2020-09-11 2020-09-11
US62/706,819 2020-09-11
US202063198971P 2020-11-25 2020-11-25
US63/198,971 2020-11-25
US202063199265P 2020-12-16 2020-12-16
US63/199,265 2020-12-16
US202163149196P 2021-02-12 2021-02-12
US63/149,196 2021-02-12
US202163175318P 2021-04-15 2021-04-15
US63/175,318 2021-04-15
PCT/EP2021/074928 WO2022053608A1 (en) 2020-09-10 2021-09-10 Novel treatment regimen for the treatment of autoimmune disorders

Publications (2)

Publication Number Publication Date
JP2023541877A JP2023541877A (ja) 2023-10-04
JP2023541877A5 true JP2023541877A5 (https=) 2024-09-20

Family

ID=78080246

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515725A Pending JP2023541877A (ja) 2020-09-10 2021-09-10 自己免疫障害の処置のための新規の処置レジメン

Country Status (10)

Country Link
US (5) US20240226284A1 (https=)
EP (1) EP4210710A1 (https=)
JP (1) JP2023541877A (https=)
KR (1) KR20230066402A (https=)
AU (1) AU2021342333A1 (https=)
BR (1) BR112023003432A2 (https=)
CA (1) CA3194812A1 (https=)
IL (1) IL301246A (https=)
MX (1) MX2023002843A (https=)
WO (1) WO2022053608A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023003432A2 (pt) 2020-09-10 2023-03-21 Merck Patent Gmbh Regime de tratamento para o tratamento de doenças autoimunes
AU2023293707A1 (en) 2022-06-15 2025-01-23 Vektor Pharma Tf Gmbh Sublingual formulation of anticancer compound for use in the treatment of autoimmune neurodegenerative diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3273787D1 (en) 1981-02-04 1986-11-20 Japan Found Cancer Human interferon-beta gene
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
JPS62153300A (ja) 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
US5106837A (en) 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US4964848A (en) 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ES2145744T5 (es) 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
EP0801571B1 (en) 1994-12-22 2002-09-04 Ortho Pharmaceutical Corporation Soluble 2-chloro-2'-deoxyadenosine formulations
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6800616B2 (en) 1998-02-26 2004-10-05 Supergen, Inc. Treatment of HIV infections
EE05214B1 (et) 1998-04-28 2009-10-15 Applied Research Systems ARS Holding N.V. Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
BR9915548A (pt) 1998-10-16 2001-08-14 Biogen Inc Proteìnas de fusão de interferon-beta e usos
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
FR2792480B1 (fr) 1999-04-19 2001-06-15 France Telecom Systeme de mise en oeuvre de services telephoniques
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
US7754855B1 (en) 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
EP1556400B1 (en) 2002-09-25 2013-05-01 Brigham Young University Method for the preparation of 2-halo-2 -deoxyadenosine compounds from 2 -deoxyguanosine
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
WO2004075903A1 (en) 2003-02-25 2004-09-10 Applied Research Systems Ars Holding N.V. Combined use of ribavirin and interferon beta in demyelinating diseases
WO2004087100A2 (en) 2003-03-28 2004-10-14 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
DK2272503T3 (da) 2003-03-28 2013-05-21 Ares Trading Sa Orale formuleringer af cladribin
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
MXPA04010902A (es) * 2004-11-03 2006-05-08 Alvaro Raul Lara Rodriguez Vacuna recombinante a partir de las proteinas ge, gi y gb del virus de varicela zoster como tratamiento y prevencion de esclerosis multiple.
EP2275110B1 (en) 2004-12-22 2013-07-10 Merck Serono SA Cladribine regimen for treating Multiple Sclerosis
WO2007135172A2 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
AR113906A1 (es) 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
BR112023003432A2 (pt) 2020-09-10 2023-03-21 Merck Patent Gmbh Regime de tratamento para o tratamento de doenças autoimunes

Similar Documents

Publication Publication Date Title
JP2023052458A5 (https=)
JP2019514858A5 (https=)
JP2019535665A5 (https=)
RU2676333C2 (ru) Способы снижения частоты приступов астмы с применением бенрализумаба
JP2016516016A5 (https=)
JP2023541877A5 (https=)
Lee et al. Tetanus–diphtheria–acellular pertussis vaccination for adults: an update
US20160136264A1 (en) Hepatitis b vaccine
US6903100B2 (en) Use of regularly scheduled high dose intravenous methotrexate therapy, with interim administration of immunomodulatory agents, to treat multiple sclerosis and other diseases of the central nervous system
JP2021525729A5 (https=)
Kremer et al. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial
IL274098B2 (en) Glp-2 analogs and peptibodies for administration before during, or after surgery
Pittet et al. Does bacillus Calmette‐Guérin vaccine prevent herpes simplex virus recurrences? A systematic review
JP2015172060A5 (https=)
JP2022531251A5 (https=)
JP2023513220A5 (https=)
AU2021382954B2 (en) Pharmaceutical composition, pharmaceutical combined formulation, and combined formulation kit for prevention or treatment of chronic hepatitis b, each comprising, as active ingredient, oral antiviral agent and therapeutic vaccine including lipopeptide and poly(i:c) adjuvant
JP2022514561A5 (https=)
JP2025501239A5 (https=)
JP2023527059A5 (https=)
JP2022518527A5 (https=)
JP2022511673A5 (https=)
Kumar et al. A practical guide to adult vaccination for patients with autoimmune inflammatory rheumatic diseases in India
WO2024056789A1 (en) Treating hiv with cabotegravir and rilpivirine in pediatric patients
EP4419110A1 (en) Treatment of viruses with antiviral nucleosides